Clinical trials: Liraglutide
Pre-Diabetes
Improving Beta Cell Function in Mexican American Women With Prediabetes
This study will examine the benefits of weight loss alone or in combination with a GLP1 receptor agonist, liraglutide, on beta cell function in young adult Mexican American (MA) women with prediabetes.
- Trial name
- NCT02488057
- Testing
- Liraglutide, Weight loss
- Where
- 4 sites in United States
- Volunteers
- 360 people
- Sponsor
- Ohio State University
Type 2 Diabetes Mellitus
Pharmacodynamic Effects of Lixisenatide Compared to Liraglutide in Patients With Type 2 Diabetes Not Adequately Controlled With Insulin Glargine With or Without Metformin
Primary Objective: To investigate the effects of repeated subcutaneous doses of lixisenatide 20 μg once daily (QD) as compared to liraglutide 1.2 mg QD or 1.8 mg QD in reducing post-prandial plasma glucose (PPG) assessed as area…
- Trial name
- NCT01596504
- Testing
- Lixisenatide (AVE0010), Liraglutide, Insulin Glargine
- Where
- 8 sites in Germany
- Volunteers
- 142 people
- Sponsor
- Sanofi
Metabolism and Nutrition Disorder, Obesity
The Effect of Liraglutide on Body Weight in Obese Subjects Without Diabetes
This trial is conducted in Europe. The purpose of the 20-week trial is to investigate the efficacy of liraglutide to induce body weight loss and the purpose of the extension is to evaluate the long term safety and tolerability of…
- Trial name
- NCT00422058
- Testing
- liraglutide, orlistat
- Where
- 19 sites in Belgium, Czechia and 6 more
- Volunteers
- 564 people
- Sponsor
- Novo Nordisk A/S
Obesity
To Investigate the Safety, Tolerability and Pharmacodynamics of GSK2890457 in Healthy Volunteers and Subjects With Type 2 Diabetes
This study is the first administration of GSK2890457 in humans. The study will be conducted in 3 parts: - Part A (conducted at a single investigative site) will determine the safety and tolerability of GSK2890457 alone in healthy…
- Trial name
- NCT01725126
- Testing
- GSK2890457, Metformin, Liraglutide
- Where
- 3 sites in United States
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Type 1 Diabetes
Incretin-based Therapy in Late Preclinical Type 1 Diabetes
The objective of the trial is to study whether daily treatment with liraglutide improves endogenous insulin secretion, postpones progression to overt Type 1 diabetes, and is tolerable and safe in subjects aged 10-30 years, who…
- Trial name
- NCT02898506
- Testing
- Victoza®
- Where
- 4 sites in Finland, Sweden
- Volunteers
- 13 people
- Sponsor
- University of Oulu
Obesity, Overweight
A Study of Tirzepatide in Overweight and Very Overweight Participants
The main purpose of this study is to measure the effect of tirzepatide on food intake in participants who are overweight or very overweight.
- Trial name
- NCT04311411
- Testing
- Tirzepatide, Liraglutide
- Where
- 3 sites in United States
- Volunteers
- 114 people
- Sponsor
- Eli Lilly and Company
Obesity, Weight Loss
Saxenda in Obesity Services (STRIVE Study)
A two year, parallel, two group, open-label, real-world randomised controlled trial (RCT) design for subjects with severe and complex obesity who are referred to a Tier 3 or equivalent specialist weight management/obesity…
- Conditions
- Obesity, Weight Loss, Diabetes Mellitus
- Trial name
- STRIVE (NCT03036800)
- Testing
- Saxenda, Specialist Obesity Management Services
- Where
- 5 sites in Ireland, United Kingdom
- Volunteers
- 392 people
- Sponsor
- University of Leicester
Healthy
A Study in Men With Overweight to Test How Well Different Doses of BI 1820237 Are Tolerated When Given as an Injection Alone or in Combination With Liraglutide
The main objective of this trial is to investigate safety, tolerability and pharmacokinetics (PK) and pharmacodynamics (PD) of BI 1820237 alone or together with a single low dose of liraglutide in male subjects with…
- Trial name
- NCT04903509
- Testing
- BI 1820237, Saxenda®, Paracetamol-ratiopharm®
- Where
- Germany
- Volunteers
- 95 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Obesity
Study to Evaluate the Safety and Effectiveness of Saxenda® for Weight Management in Routine Clinical Practice in Taiwan.
This is a non-interventional study to evaluate the safety and effectiveness of Saxenda® in obese adults and adolescents in Taiwan.
- Trial name
- NCT06283641
- Testing
- Liraglutide
- Where
- 15 sites in Taiwan
- Volunteers
- 300 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
Study of the Safety and Tolerability of Switching to ITCA 650 in Patients With Type 2 Diabetes Receiving Liraglutide
A Phase 3b, open-label, randomized, multicenter, safety and tolerability study of ITCA 650 in subjects with Type 2 diabetes taking liraglutide and metformin.
- Trial name
- NCT02638805
- Testing
- ITCA 650 Osmotic Mini Pump 20/60 mcg/day, ITCA 650 Osmotic Mini Pump 60 mcg/day, Metformin
- Where
- 36 sites in United States
- Volunteers
- 136 people
- Sponsor
- Intarcia Therapeutics
Type 1 Diabetes
Liraglutide in the Treatment of Type 1 Diabetes Mellitus
Hypothesis 1: Treatment with Liraglutide in patients with type 1 diabetes decreases fasting, postprandial and the overall mean glucose concentrations.
- Trial name
- NCT01722266
- Testing
- Liraglutide
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- University at Buffalo
Type 2 Diabetes
Study of Liraglutide in Individuals With Type 2 Diabetes Using Insulin
Liraglutide is a GLP1 agonist used in the treatment of Type 2 diabetes and is is asociated with improved blood glucose control, weight loss and low rates of hypoglycemia when used alone or in combination with metformin.
- Trial name
- SAIL (NCT01628445)
- Testing
- liraglutide
- Where
- Canada
- Volunteers
- 52 people
- Sponsor
- University of Manitoba
Diabetes, Diabetes Mellitus, Type 2
A 104 Week Clinical Trial Comparing Long Term Glycaemic Control of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine Therapy in Subjects With Type 2 Diabetes Mellitus
This trial is conducted in Africa, Asia, Europe, North America and South America. The purpose is to compare long-term glycaemic control of insulin degludec/liraglutide (IDegLira) versus insulin glargine (IGlar) in insulin naïve…
- Trial name
- DUAL™ VIII (NCT02501161)
- Testing
- insulin degludec/liraglutide, insulin glargine
- Where
- 143 sites in United States, Argentina and 14 more
- Volunteers
- 1,012 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
Effect of Liraglutide on the Beta-cell Responsiveness in Subjects With Type 2 Diabetes Compared to a Healthy Control Group
This trial is conducted in the United States of America (USA). The aim of this trial is to assess the effect of NNC 90-1170 on beta-cell responsiveness to increasing blood glucose concentrations in subjects with type 2 diabetes.
- Trial name
- NCT01511185
- Testing
- liraglutide
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Novo Nordisk A/S
Metformin, Obesity, Abdominal
Effects of GLP-1RA on Body Weight, Metabolism and Fat Distribution in Overweight/Obese Patients With Type 2 Diabetes Mellitus
The purpose of this study is to analyze the effects of GLP-1RA on blood glucose, body weight, glucose and lipid metabolism and fat distribution in overweight/obese patients with type 2 diabetes mellitus.
- Conditions
- Metformin, Obesity, Abdominal, Diabetes Mellitus, Type 2, Abdominal Fat
- Trial name
- NCT05779644
- Testing
- Liraglutide, Semaglutide, Metformin
- Where
- China
- Volunteers
- 300 people
- Sponsor
- RenJi Hospital
PCOS, Obesity
Liraglutide Treatment in Obese Infertile PCOS Women
Liraglutide, a hypoglycemic drug, can reduce weight and improve insulin resistance while stabilizing blood glucose metabolism without increasing the risk of hypoglycemia, and has been approved by the State Food and Drug…
- Conditions
- PCOS, Obesity, Infertility
- Trial name
- LITOP (NCT06742710)
- Testing
- Liraglutide and metformin, Metformin
- Where
- 3 sites in China
- Volunteers
- 890 people
- Sponsor
- Peking University Third Hospital
Diabetes, Diabetes Mellitus, Type 2
A Trial to Investigate the Single Dose Pharmacokinetics of Insulin Degludec/Liraglutide Compared With Insulin Degludec and Liraglutide in Healthy Chinese Subjects
The main purpose of the trial is to compare the bioavailability (extent of drug absorption into the circulation) of insulin degludec and liraglutide as part of a combination product insulin degludec/liraglutide compared to the…
- Trial name
- NCT03292185
- Testing
- insulin degludec/liraglutide, insulin degludec, liraglutide
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus Type II
Perioperative Insulin, GIK or GLP-1 Treatment in Diabetes Mellitus
The incidence of diabetes mellitus type II is increasing. More and more patients who need surgery have diabetes mellitus type II.
- Trial name
- PILGRIM (NCT02036372)
- Testing
- Liraglutide, Insulin bolus, GIK infusion
- Where
- 3 sites in Netherlands
- Volunteers
- 150 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Diabetes, Diabetes Mellitus, Type 2
Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes
This trial is conducted globally. The aim of the trial is to investigate efficacy in controlling glycaemia with Victoza® (liraglutide) as add-on to metformin background treatment vs.
- Trial name
- LIRA-PRIME (NCT02730377)
- Testing
- liraglutide, alpha-glucosidase inhibitors, DPP-4 inhibitors
- Where
- 232 sites in United States, Canada and 8 more
- Volunteers
- 1,991 people
- Sponsor
- Novo Nordisk A/S
Obesity
Effects of XW003 Versus Liraglutide on Body Weight of Adult Participants With Obesity
XW003 is an acylated human glucagon-like peptide 1 (GLP-1) analogue and is being developed for type 2 diabetes mellitus (T2DM) and obesity management.
- Trial name
- NCT05111912
- Testing
- XW003, Saxenda
- Where
- Australia
- Volunteers
- 206 people
- Sponsor
- Sciwind Biosciences APAC CO Pty. Ltd.